Thorne Research   Report issue

For profit Phase 2
Founded: New York NY United States (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2015
NCT02663479
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Thorne Research Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

curcumin (1 trial)

vasopressin (vasostrict) (1 trial)

Drugs in Other Trials (2)

nicotinamide (1 trial)

quercetin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Hypertension (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4